



AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions:


Listing of Claims:

1. (currently amended) A method of treating myelodysplastic syndromes, lymphomas and leukemias , and solid tumors comprising cells that express constitutively active mutant FLT-3 in a mammal which comprises treating the mammal in need of such treatment simultaneously, concurrently, separately or sequentially with pharmaceutically effective amounts of (a) a FLT-3 inhibitor, or a pharmaceutically acceptable salt ~~or a prodrug~~ thereof, and (b) a histone deacetylase inhibitor (HDAI), or a pharmaceutically acceptable salt or a prodrug thereof.
2. (original) The method according to claim 1 for treating acute myeloid leukemia (AML) .
3. (cancelled)
4. (currently amended) The method according to claim 1, wherein the FLT-3 inhibitor is a staurosporine derivative ~~is selected from the compounds of formula,~~







or



or



or



or

wherein R₁ and R₂, are, independently of one another, unsubstituted or substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;

n and m are, independently of one another, a number from 0 to 4;

n' and m' are, independently of one another, a number from 1 to 4:

R₃, R₄, R₈ and R₁₀ are, independently of one another, hydrogen, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, an acyl with up to 30 carbon atoms, wherein R₄ may also be absent;

or R₃ is acyl with up to 30 carbon atoms and R₄ not an acyl;

p is 0 if R₄ is absent, or is 1 if R₃ and R₄ are both present and in each case are one of the aforementioned radicals;

R₅ is hydrogen, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms;

R₇, R₆ and R₉ are acyl or –(lower alkyl) –acyl, unsubstituted or substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, carbonyl, carbonyldioxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;

X stands for 2 hydrogen atoms; for 1 hydrogen atom and hydroxy; for O; or for hydrogen and lower alkoxy;

Z stands for hydrogen or lower alkyl;


and either the two bonds characterised by wavy lines are absent in ring A and replaced by 4 hydrogen atoms, and the two wavy lines in ring B each, together with the respective parallel bond, signify a double bond;

or the two bonds characterised by wavy lines are absent in ring B and replaced by a total of 4 hydrogen atoms, and the two wavy lines in ring A each, together with the respective parallel bond, signify a double bond;

or both in ring A and in ring B all of the 4 wavy bonds are absent and are replaced by a total of 8 hydrogen atoms;

or a salt thereof, if at least one salt-forming group is present.

5. (currently amended) The method according to claim 4 3, wherein the staurosporine derivative is a staurosporin derivative of formula I,



wherein

m and n are each 0;

R₃ and R₄ are independently of each other

hydrogen,

lower alkyl unsubstituted or mono- or disubstituted, especially monosubstituted, by radicals selected independently of one another from carboxy; lower alkoxy carbonyl; and cyano;

or

R₄ is hydrogen or -CH₃, and

R₃ is acyl of the subformula R^o-CO-, wherein R^o is lower alkyl; amino-lower alkyl, wherein the amino group is present in unprotected form or is protected by lower alkoxy carbonyl; tetrahydropyranyloxy-lower alkyl; phenyl; imidazolyl-lower alkoxyphenyl; carboxyphenyl; lower alkoxy carbonylphenyl; halogen-lower alkylphenyl; imidazol-1-ylphenyl; pyrrolidino-lower alkylphenyl; piperazino-lower alkylphenyl; (4-lower alkylpiperazinomethyl)phenyl; morpholino-lower alkylphenyl; piperazinocarbonylphenyl; or (4-lower alkylpiperazino)phenyl;

or is acyl of the subformula R^o-O-CO-, wherein R^o is lower alkyl;

or is acyl of the subformula R^oHN-C(=W)-, wherein W is oxygen and R^o has the following meanings: morpholino-lower alkyl, phenyl, lower alkoxyphenyl, carboxyphenyl, or lower alkoxy carbonylphenyl;

or R₃ is lower alkylphenylsulfonyl, typically 4-toluenesulfonyl;

R₅ is hydrogen or lower alkyl,


X stands for 2 hydrogen atoms or for O;

Z is methyl or hydrogen;

or a salt thereof, if at least one salt-forming group is present.


6. (currently amended) The method according to claim 4, wherein the staurosporine derivative is *N*-[(9*S*,10*R*,11*R*,13*R*)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-

epoxy-1*H*,9*H*-diindolo[1,2,3-*gh*:3',2',1'-*lm*]pyrrolo[3,4-*j*][1,7]benzodiazonin-11-yl]-*N*-methylbenzamide of the formula (VII):



or a salt thereof.

7. (original) The method according to claim 1, wherein the HDAl compound is a histone deacetylase inhibitor of formula (X)



wherein

R_1 is H, halo, or a straight chain C_1 - C_6 alkyl;

R_2 is selected from H, C_1 - C_{10} alkyl, C_4 - C_9 cycloalkyl, C_4 - C_9 heterocycloalkyl, C_4 - C_9 heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, $-(CH_2)_nC(O)R_6$, $-(CH_2)_nOC(O)R_6$, amino acyl, $HON-C(O)-CH=C(R_1)$ -aryl-alkyl- and $-(CH_2)_nR_7$;

R_3 and R_4 are the same or different and independently H, C_1 - C_6 alkyl, acyl or acylamino, or R_3 and R_4 together with the carbon to which they are bound represent $C=O$, $C=S$, or $C=NR_8$, or R_2 together with the nitrogen to which it is bound and R_3 together with the carbon to which it is bound can form a C_4 - C_9 heterocycloalkyl, a heteroaryl, a

polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring;

R₅ is selected from H, C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aromatic polycycle, non-aromatic polycycle, mixed aryl and non-aryl polycycle, polyheteroaryl, non-aromatic polyheterocycle, and mixed aryl and non-aryl polyheterocycle;

n, n₁, n₂ and n₃ are the same or different and independently selected from 0 - 6, when n₁ is 1-6, each carbon atom can be optionally and independently substituted with R₃ and/or R₄;

X and Y are the same or different and independently selected from H, halo, C₁-C₄ alkyl, NO₂, C(O)R₁, OR₉, SR₉, CN, and NR₁₀R₁₁;

R₆ is selected from H, C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, OR₁₂, and NR₁₃R₁₄;

R₇ is selected from OR₁₅, SR₁₅, S(O)R₁₆, SO₂R₁₇, NR₁₃R₁₄, and NR₁₂SO₂R₆;

R₈ is selected from H, OR₁₅, NR₁₃R₁₄, C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl;

R₉ is selected from C₁ - C₄ alkyl and C(O)-alkyl;

R₁₀ and R₁₁ are the same or different and independently selected from H, C₁-C₄ alkyl, and -C(O)-alkyl;

R₁₂ is selected from H, C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, C₄ - C₉ heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl, and heteroarylalkyl;

R₁₃ and R₁₄ are the same or different and independently selected from H, C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, amino acyl, or R₁₃ and R₁₄ together with the nitrogen to which they are bound are C₄ - C₉ heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle;

R₁₅ is selected from H, C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH₂)_mZR₁₂;

R₁₆ is selected from C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH₂)_mZR₁₂;

R₁₇ is selected from C₁-C₆ alkyl, C₄ - C₉ cycloalkyl, C₄ - C₉ heterocycloalkyl, aryl, aromatic polycycle, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and NR₁₃R₁₄;

m is an integer selected from 0 to 6; and

Z is selected from O, NR₁₃, S and S(O);


or a pharmaceutically acceptable salt thereof.

8. (original) The method according to claim 7, wherein each of R₁, X, Y, R₃, and R₄ is H.

9. (original) The method according to claim 8, wherein one of n_2 and n_3 is zero and the other is 1.

10. (original) The method according to claim 9, wherein one of n_2 and n_3 is zero and the other is 1.

11. (original) The method according to claim 1, wherein the histone deacetylase inhibitor is a compound of the formula (Xa)




wherein

n_4 is 0-3,

R_2 is selected from H, C_1 - C_6 alkyl, C_4 - C_9 cycloalkyl, C_4 - C_9 heterocycloalkyl, alkylcycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, $-(CH_2)_nC(O)R_6$, amino acyl and $-(CH_2)_nR_7$;

R_5' is heteroaryl, heteroarylalkyl, an aromatic polycycle, a non-aromatic polycycle, a mixed aryl and non-aryl polycycle, polyheteroaryl, or a mixed aryl and non-aryl polyheterocycle or a pharmaceutically acceptable salt thereof.

12. (original) The method according to claim 1, wherein the histone deacetylase inhibitor is a compound of the formula (Xb):




wherein

R_2' is selected from H, C_1 - C_6 alkyl, C_4 - C_6 cycloalkyl, alkylcycloalkyl, and $(CH_2)_{2-4}OR_{21}$ where R_{21} is H, methyl, ethyl, propyl, or isopropyl, and

R_5'' is unsubstituted or substituted 1*H*-indol-3-yl, benzofuran-3-yl or quinolin-3-yl or a pharmaceutically acceptable salt thereof.

13. (original) The method according to claim 1, wherein the histone deacetylase inhibitor is a compound of the formula

(Xe)



or a pharmaceutically acceptable salt thereof.

14. (currently amended) The method according to ~~any one of~~ claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of N-hydroxy-3-[4-[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or, in each case a pharmaceutically acceptable salt thereof.


Claims 15-20 (cancelled).

21. (withdrawn) A pharmaceutical composition comprising (a) a FLT-3 inhibitor and (b) a histone deacetylase inhibitor for the treatment of myelodysplastic syndromes, lymphomas and leukemias and solid tumors.

22. (withdrawn) A pharmaceutical composition according to claim 21 for treating acute myeloid leukemia (AML), colorectal cancer (CRC) or non-small cell lung cancer (NSCLC).

23. (withdrawn) A pharmaceutical composition according to claim 21, wherein the FLT-3 inhibitor is -[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide of the formula (VII):

24. (new) The method according to claim 2, wherein the staurosporine derivative is N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide of the formula (VII):



(VII)

or a salt thereof and the HDAI is selected from the group consisting of N-hydroxy-3-[4-[[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or, in each case a pharmaceutically acceptable salt thereof.